Developments on tumour site-specific chrono-oncology towards personalised treatment

Marcu, Loredana G.

doi:10.1016/j.critrevonc.2022.103803

Cited by 3 publications

(1 citation statement)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical trials have evaluated the relevance of circadian timing for nearly 20 anticancer agents in colorectal, lung, breast, stomach, pancreatic, kidney, bladder, endometrial, ovarian, head and neck, skin, brain, and hematologic cancers (114). A systematic review of chronomodulated chemotherapy identified 18 randomized trials involving at least one group with chronomodulated chemotherapy and a total of 2,547 cancer patients (115).…”

Section: Cytotoxic Anticancer Agentsmentioning

confidence: 99%

Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy

Lévi,

Okyar,

Hadadi

et al. 2024

Annu. Rev. Pharmacol. Toxicol.

View full text Add to dashboard Cite

Today's challenge for precision medicine involves the integration of the impact of molecular clocks on drug pharmacokinetics, toxicity, and efficacy, toward personalized chronotherapy. Meaningful improvements of tolerability and/or efficacy of medications through proper administration timing have been confirmed over the past decade for immunotherapy and chemotherapy against cancer, as well as for commonly used pharmacological agents in cardiovascular, metabolic, inflammatory, and neurological conditions. Experimental and human studies have recently revealed sexually dimorphic circadian drug responses. Dedicated randomized clinical trials should now aim to issue personalized circadian timing recommendations for daily medical practice, integrating innovative technologies for remote longitudinal monitoring of circadian metrics, statistical prediction of molecular clock function from single-timepoint biopsies, and multiscale biorhythmic mathematical modelling. Importantly, chronofit patients with a robust circadian function, who would benefit most from personalized chronotherapy, need to be identified. Conversely, nonchronofit patients could benefit from the emerging pharmacological class of chronobiotics targeting the circadian clock. Expected final online publication date for the Annual Review of Pharmacology and Toxicology, Volume 64 is January 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

show abstract

Section: Cytotoxic Anticancer Agentsmentioning

confidence: 99%